Factors | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
n | Medium RFS (m) | HR, (95% CI) | P- value | HR, (95% CI) | P- alue | |
Age (years) | Â | Â | Â | Â | Â | Â |
 <55 | 108 | 12.9 | 1.16, (0.86 to 1.55) | 0.327 | — | — |
 ≥55 | 224 | 14.7 | 1 |  |  |  |
Gender | Â | Â | Â | Â | Â | Â |
 Male | 225 | 15.1 | 1 | 0.608 | — | — |
 Female | 107 | 11.2 | 1.08, (0.80 to 1.45) |  |  |  |
Primary tumor | Â | Â | Â | Â | Â | Â |
 Colon | 206 | 15.1 | 1 | 0.232 | — | — |
 Rectum | 126 | 12.0 | 1.11, (0.89 to 1.57) |  |  |  |
Serum CEA (ng/mL) | Â | Â | Â | Â | Â | Â |
 <100 | 294 | 15.1 | 1 | <0.0001 | 1 | 0.001 |
 ≥100 | 38 | 6.3 | 3.15, (1.83 to 5.44) |  | 2.06, (1.36 to 3.11) |  |
Metastatic type | Â | Â | Â | Â | Â | Â |
 Synchronous | 153 | 14.8 | 1 | 0.757 | 1 | 0.744 |
 Metachronous | 179 | 13.1 | 0.95, (0.72 to 1.26) |  | 1.05, (0.79 to 1.40) |  |
Number of tumors | Â | Â | Â | Â | Â | Â |
 <4 nodules | 285 | 15.4 | 1 | 0.001 | 1 | 0.041 |
 ≥4 nodules | 47 | 8.3 | 2.22, (1.40 to 3.51) |  | 1.53, (1.02 to 2.29) |  |
Maximum tumor size (cm) | Â | Â | Â | Â | Â | Â |
 <5 | 267 | 13.6 | 1.39, (0.99 to 1.95) | 0.058 | 1.40, (0.95 to 2.06) | 0.088 |
 ≥5 | 65 | 21.7 | 1 |  | 1 |  |
Distribution of metastasis | Â | Â | Â | Â | Â | Â |
 Unilobar | 239 | 15.9 | 1 | 0.025 | 1 | 0.399 |
 Bilobar | 93 | 9.7 | 1.43, (1.40 to 1.98) |  | 1.16, (0.82 to 1.63) |  |
Extent of liver resection | Â | Â | Â | Â | Â | Â |
 <3 segments | 262 | 14.6 | 1 | 0.751 | — | — |
 ≥3 segments | 70 | 13.1 | 0.95, (0.68 to 1.32) |  |  |  |
Resection margin (mm) | Â | Â | Â | Â | Â | Â |
 <0.5 | 142 | 11.5 | 1.42, (1.08 to 1.88) | 0.012 | 1.28, (0.95 to 1.71) | 0.103 |
 ≥0.5 | 190 | 16.8 | 1 |  | 1 |  |
Histologic grade | Â | Â | Â | Â | Â | Â |
 Low-moderate grade | 321 | 14.4 | 1 | 0.112 | 1 | 0.237 |
 High grade | 11 | 6.9 | 1.92, (0.86 to 4.28) |  | 1.50, (0.77 to 2.94) |  |
Postoperative chemotherapy | Â | Â | Â | Â | Â | Â |
 Fluorouracil | 57 | 12.5 | 1.28, (0.85 to 1.93) | 0.326 | 1.19, (0.80 to 1.76) | 0.712 |
 Oxaliplatin base | 140 | 16.8 | 1 |  | 1 |  |
 Irinotecan base | 103 | 12.8 | 1.34, (0.85 to 1.93) |  | 1.19, (0.85 to 1.65) |  |
 No | 32 | 13.6 | 1.00, (0.60 to 1.67) |  | 1.15, (0.68 to 1.95) |  |
Associated with bevacizumab | Â | Â | Â | Â | Â | Â |
 Yes | 46 | 17.0 | 1 | 0.496 | — | — |
 No | 286 | 13.5 | 1.15, (0.77 to 1.72) |  |  |  |
Associated with cetuximab | Â | Â | Â | Â | Â | Â |
 Yes | 6 | 7.4 | 1.80, (0.52 to 6.25) | 0.352 | — | — |
 No | 326 | 14.4 | 1 |  |  |  |
Chemotherapy cycles | Â | Â | Â | Â | Â | Â |
 ≥6 | 232 | 15.4 | 1 | 0.233 | — | — |
 <6 | 100 | 9.7 | 1.21, (0.89 to 1.65) |  |  |  |